evelyne Crapez

Head of translational Research Unit (MD, PhD)

Institut de Recherche en Cancérologie de Montpellier

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Evelyne Crapez is the Head of the Translational Research Unit at the Institut régional du Cancer de Montpellier, France. Her research focuses on cancer biology, specifically the regulation of epithelial–mesenchymal transition, immune infiltration in breast cancer, and survival mechanisms in various carcinomas. Her recent articles examine topics such as the molecular features of treatment responses, the prognostic relevance of specific gene mutations, and novel therapeutic strategies in advanced malignancies.

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Institut de Recherche en Cancérologie de Montpellier

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

evelyne Crapez

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

PTPN13 Participates in the Regulation of Epithelial–Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells

Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer

A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors

Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers

Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).

Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.

Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).

<i>BRCA1</i> Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.

Collaborators (8)

Angélique Bobrie

François Bertucci

Vincent Cavaillès

Max CHAFFANET

Stéphan Jalaguier

Florence Boissière-Michot

Virginie Lafont

Gilles Freiss

Make your next move.